Position in SVTR
Snapshot 2026-10-26- Startup SignalsTop 25%new
- Life SciencesTop 25%
- Medtech Device#2of 43
- Medical Diagnosis#3of 20
- Medical Imaging#2of 17
About
Promaxo builds a point-of-care low-field MRI platform with AI-driven cancer risk scoring and robotic guidance for in-office prostate biopsy and treatment.
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Investor· 2
Founders / team· 2
Funding history
- 2026-10-22Equity + Debt$100M
Investors · New Science Ventures, Amara VenturesSource · finance.yahoo.com ↗
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Promaxo
Promaxo builds a point-of-care low-field MRI platform with AI-driven cancer risk scoring and robotic guidance for in-office prostate biopsy and treatment.
Equity + Debt · 2026-10
—
United States
BusinessLatest roundTotal raisedDate- Mira
Mira (Quanovate Tech Inc.) is a US women's health technology company that makes the Mira at-home hormone monitor, which pairs disposable test wands with an AI-powered app to track LH, E3G, PdG and FSH for fertility, PCOS and perimenopause. It is FDA-registered and Health Canada licensed, with users in 40+ countries.
$5M
$5M - Epitel
Wireless wearable remote EEG monitoring system (REMI) + AI seizure event detection (REMI Vigilenz)
Series B · $39M · 2026-07
$39M - Epsilon Health
AI-native radiology practice: AI embedded in physicians' diagnostic workflows speeds image interpretation while retaining physician review
Series A · 2026-09
—
China
BusinessLatest roundTotal raisedDate- 睿心医疗
Developer of AI precision diagnosis and treatment platforms for cardiovascular and cerebrovascular disease and of vascular interventional surgical robots.
Strategic · 2026-07
— - 湾影科技
Brain metabolic imaging technology
Undisclosed · 2026-07
— - Krinwave
Super-resolution ultrasound imaging systems (kOS ultrasound operating system + HUS hardware platform), focused on transcranial brain ultrasound and clinical/research ultrasound diagnostics
Undisclosed · 2026-10
—
Europe
BusinessLatest roundTotal raisedDate- Implicity
Data aggregation and AI risk alert platform for remote monitoring of cardiac implantable electronic devices (CIEDs)
Undisclosed · 2026-09
— - MyndBlue
Wearable and AI-based remote objective monitoring and early warning for depression and PTSD
— - Vitestro
Developed a device that integrates AI with ultrasound imaging and robotics to automate blood collection
Series B · $120M · 2026-03
$120M
Other / unspecified
BusinessLatest roundTotal raisedDate- Scopia Surgical
AI surgical navigation software combining real-time spatial intelligence and patient-specific digital twins for robot-assisted and minimally invasive soft-tissue surgery
Pre-Seed · $3M · 2026-09
$3M - UltraSight
AI-guided cardiac ultrasound workflow platform (Echosystem) enabling non-specialist clinicians to perform diagnostic-grade echocardiograms at the bedside
Series B · $42M · 2026-09
$42M - Oncoustics
Point-of-care ultrasound AI software (OnX platform) for non-invasive liver disease detection and monitoring from raw acoustic signals ("virtual biopsy")
$764K
$764K
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Andreessen Horowitz
24 Life Sciences deals in the last 24 months · 22 in Silicon Valley
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.